

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1.-29. (cancelled)

30. (currently amended) A hemocompatible surface of an article, device, or material, the hemocompatible surface consisting of:

~~a material located on or in the hemocompatible surface, wherein the material consists of an artificial compound, a natural organic compound, or an inorganic compound, or a mixture thereof; and,~~

a constituent of an outer layer of a blood cell, a constituent of an outer layer of a mesothelial cell or a combination thereof, and

~~wherein the hemocompatible surface does~~ neither activate nor actively suppress a blood coagulation system when having direct contact with blood not comprise thrombodin and with the proviso that the hemocompatible surface does not comprise whole, intact cells.

31. (currently amended) The hemocompatible surface of claim 30, wherein the article, device, or material is hemocompatible surface ~~consists of a natural organic compound and a constituent of an outer layer of a blood cell, a constituent of an outer layer of a mesothelial cell or a combination thereof,~~

~~the hemocompatible surface consisting of a surface extracted from an~~ animal organ, an animal organ part, a vascular system, or a combination thereof.

32. (previously presented) The hemocompatible surface of claim 30, wherein the constituent consists of:

an oligosaccharide;
a polysaccharide;
lipid portions of a glycoprotein, lipid portions of a glycolipid, or lipid portions of a proteoglycan; or
combinations thereof;
wherein the constituent is obtained from outer layers of blood cells, outer layers of mesothelial cells, or combinations thereof.

33. (previously presented) The hemocompatible surface of claim 30, wherein the constituent consists of heparin sulfate obtained from erythrocyte plasma membranes of animals or humans.

34. (previously presented) The hemocompatible surface of claim 30, wherein the constituent consists of an oligosaccharide or a polysaccharide portion of a proteoglycan, wherein the proteoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin sulfate, or keratin sulfate, or a mixture thereof.

35. (previously presented) The hemocompatible surface of claim 30, wherein the constituent consists of glycoporphins, glycosphingolipids, or combinations thereof.

36. (previously presented) The hemocompatible surface of claim 30, wherein the hemocompatible surface is non-thrombogenic, non-immunogenic or a combination thereof.

37. (currently amended) The hemocompatible surface of claim 30, wherein the article, device, or material consists of a high-molecular weight organic compound, a metal, a metal oxide, an alloy, a ceramic, a glass, a mineral, or a mixture thereof.

38. (currently amended) ~~An~~ The article, device, or material comprising the hemocompatible surface of claim 30.

39. (currently amended) A hemocompatible surface of an article, device, or material, the hemocompatible surface comprising:

~~a material located on or in the hemocompatible surface, wherein the material comprises~~ an artificial compound, a natural organic compound, or an inorganic compound, or a mixture thereof; and,

a non-thrombogenic constituent of an outer layer of a blood cell, a non-thrombogenic constituent of an outer layer of a mesothelial cell or a combination thereof, the non-thrombogenic constituent separated and isolated from at least one of blood cells and mesothelial cells, the non-thrombogenic constituent consisting of an oligosaccharide; a polysaccharide; lipid portions of a glycoprotein, lipid portions of a glycolipid, or lipid portions of a proteoglycan; or combinations thereof, and

wherein the hemocompatible surface does neither activate nor actively suppress a blood coagulation system when having direct contact with blood with the proviso that the hemocompatible surface does not comprise whole, entire cells.

40. (currently amended) The hemocompatible surface of claim 39, wherein the article, device, or material is ~~hemocompatible surface comprises a natural organic compound and a non-thrombogenic constituent of an outer layer of a blood cell, a constituent of an outer layer of a mesothelial cell or a combination thereof,~~
~~the hemocompatible surface comprises a surface extracted from an animal organ, an animal organ part, a vascular system, or a combination thereof.~~

41. (previously presented) The hemocompatible surface of claim 39, wherein the non-thrombogenic constituent consists of heparin sulfate obtained from erythrocyte plasma membranes of animals or humans.

42. (previously presented) The hemocompatible surface of claim 39, wherein the non-thrombogenic constituent consists of an oligosaccharide or a polysaccharide portion of a proteoglycan, wherein the proteoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin sulfate, or keratin sulfate, or a mixture thereof.

43. (previously presented) The hemocompatible surface of claim 39, wherein the non-thrombogenic constituent consists of glycoporphins, glycosphingolipids, or combinations thereof.

44. (previously presented) The hemocompatible surface of claim 39, wherein the hemocompatible surface is non-immunogenic.

45. (currently amended) The hemocompatible surface of claim 39, wherein the article, device, or material comprises a high-molecular weight organic compound, a metal, a metal oxide, an alloy, a ceramic, a glass, a mineral, or a mixture thereof.

46. (currently amended) ~~An~~ The article, device, or material comprising the hemocompatible surface of claim 39.

47. (currently amended) A hemocompatible surface of an article, device, or material, the hemocompatible surface consisting of:

~~a material located on or in the hemocompatible surface, wherein the material consists of~~ an artificial compound, a natural organic compound, or an inorganic compound, or a mixture thereof; and,

a non-thrombogenic constituent of an outer layer of a blood cell, a non-thrombogenic constituent of an outer layer of a mesothelial cell or a combination thereof, the non-thrombogenic constituent separated and isolated from at least one of blood cells and mesothelial cells, and

wherein the hemocompatible surface does neither activate nor actively suppress a blood coagulation system when having direct contact with blood with the proviso that the hemocompatible surface does not consist of whole, entire cells.

48. (currently amended) The hemocompatible surface of claim 47, wherein the ~~article, device, or material is hemocompatible surface consists of a natural organic compound and a non-thrombogenic constituent of an outer layer of a blood cell, a non-thrombogenic constituent of an outer layer of a mesothelial cell or a combination thereof,~~

~~the hemocompatible surface consisting of a surface extracted from an~~
animal organ, an animal organ part, a vascular system, or a combination thereof.

49. (previously presented) The hemocompatible surface of claim 47, wherein the non-thrombogenic constituent consists of:

an oligosaccharide;

a polysaccharide;

lipid portions of a glycoprotein, lipid portions of a glycolipid, or lipid portions of a proteoglycan; or

combinations thereof;

wherein the non-thrombogenic constituent is obtained from outer layers of blood cells, outer layers of mesothelial cells, or combinations thereof.